Randomized Trialhigh evidence

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.

The New England journal of medicine·November 7, 2026·PMID 43001751

Why it matters

Interleukin-6 is a key inflammatory mediator implicated in atherosclerosis, and prior biomarker and genetic data suggested that lowering IL-6 could reduce cardiovascular events. This large trial directly tests that hypothesis in a high-risk population with elevated CRP and CKD, providing definitive evidence that IL-6 neutralization with ziltivekimab does not improve cardiovascular outcomes despite robust biomarker suppression.

Infographic summary of Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled